Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape

MIAMI - PrZen -- NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP has reached another important milestone, moving beyond its recent FDA approval and officially commencing commercial sales of its newly approved, American-manufactured preservative-free ketamine. In its November 11, 2026 announcement, the company confirmed that a veteran, trained, and certified 17-person national sales force commenced sales operations this week, bringing established relationships with hospital and healthcare purchasers responsible for approximately 80% of current U.S. ketamine sales. NRx is targeting initial supply agreements and preorders for late 2026, with product shipments scheduled to begin in January 2027. The company also expects gross and net sales margins in excess of 50%, based on anticipated efficiencies in its innovative blow-fill-seal manufacturing process and sales structure. Following its October 30 FDA approval, this latest announcement represents a significant transition from pharmaceutical development and regulatory preparation into commercial execution. For investors, NRXP now has a compelling collection of developments to follow: an approved product, an active sales organization, established industry relationships, commercial manufacturing capabilities, and plans to expand its domestic sterile injectable manufacturing footprint.

FDA Approval Followed by Immediate Commercial Sales Activity

The October 30 FDA approval of NRx's Abbreviated New Drug Application (ANDA) for preservative-free intravenous ketamine was a defining achievement for the company. Importantly, the approval arrived ahead of the November 10 FDA goal date, completing a major regulatory milestone that NRx had been working toward throughout the summer and fall.

The approved product offers a preservative-free formulation of ketamine without benzethonium chloride (BZT), an antimicrobial preservative used in existing ketamine injection products. NRx has emphasized the potential benefits of its alternative formulation for hospitals and clinics seeking a dependable supply of sterile injectable medication.

Today's announcement demonstrates that NRx is moving quickly to capitalize on the approval. Rather than simply announcing plans to build a commercial organization, the company has now confirmed that its 17-person sales team has commenced operations.

The team's established relationships are particularly noteworthy. According to NRx, its sales representatives have relationships with purchasers responsible for approximately 80% of current U.S. ketamine sales. This provides a substantial potential commercial reach as the company pursues supply agreements and customer orders.

The company is targeting initial agreements and preorders in late 2026, with shipments scheduled to begin in January 2027. These are important upcoming milestones for investors as the company works to convert its sales activity into actual product distribution and revenue.

An Established Sales Network and Potentially Attractive Margins

One of the more interesting aspects of the November 11 announcement is the commercial strategy behind the launch.

NRx has assembled a team of experienced pharmaceutical sales professionals, many with decades of experience in the sterile injectable market. According to CEO Jonathan Javitt, MD, MPH, these existing relationships can help the company operate more efficiently while reaching hospital and group purchasing organizations.

The company expects gross and net sales margins in excess of 50%, attributing this anticipated profitability to efficiencies in manufacturing and its sales organization.

These figures are management expectations, not demonstrated operating results, and actual margins will depend on pricing, production costs, customer agreements, and commercial execution. Nevertheless, the proposed business model is an important part of the investment story.

NRx is also highlighting its innovative blow-fill-seal (BFS) manufacturing process. Unlike traditional glass-vial manufacturing, BFS technology forms, fills, and seals the product container in a single manufacturing process. The company's needle-free vial incorporates a luer-lock tip that connects directly to a sterile syringe.

NRx believes this packaging and manufacturing approach offers several advantages, including reduced manufacturing costs, simplified handling for healthcare professionals, and a differentiated product presentation.

The company also believes the manufacturing technology could create opportunities beyond ketamine, potentially allowing it to introduce additional sterile injectable medicines through the same commercial infrastructure.

Manufacturing Expansion Could Create a Much Larger Opportunity

NRx is already looking beyond its initial ketamine launch.

In today's announcement, the company disclosed that it has contracted with German suppliers of BFS manufacturing technology to double its manufacturing footprint in South Carolina.

This is an important strategic development because it could increase production capacity while creating opportunities to expand into additional American-manufactured sterile injectable products.

NRx has identified the economics of traditional sterile injectable manufacturing as a significant industry challenge. Its strategy is to use modern manufacturing technology to improve production economics and potentially make older generic injectable medicines commercially viable for domestic manufacturing.

The company believes the BFS process can substantially reduce manufacturing costs compared with traditional glass-vial production. If the model proves successful, NRx could potentially leverage its manufacturing expansion, existing sales relationships, and distribution channels across additional products.

This makes the November 11 announcement particularly interesting: the company is not simply discussing the launch of one approved product, but also outlining a potential platform for future pharmaceutical manufacturing and commercialization.

A Significant Development: Approximately $11.25 Million DARPA Contract

Another major development over the past several months is NRx's approximately $11.25 million research contract with the Defense Advanced Research Projects Agency (DARPA).

Announced September 30, the contract supports the SPARC-TMS program, which is designed to evaluate NRX-101 in combination with robotic neuronavigated transcranial magnetic stimulation (TMS) for treatment-resistant depression.

The proposed approach investigates a single-day treatment protocol and brings together NRx Defense Systems, HOPE Therapeutics, McLean Hospital, Arizona State University, Zeta Surgical Systems, and Neurocare of America.

The program represents a potentially important opportunity to combine pharmaceutical innovation with advanced brain stimulation technology.

The contract provides a funded research opportunity with an 18-month performance period, although additional funding is subject to appropriations and contract options. Clinical outcomes will determine the potential of the treatment approach.

For investors, this initiative adds another dimension to NRx's business beyond its newly approved commercial ketamine product.

HOPE Therapeutics and Robotic Brain Stimulation Expand the Company's Reach

NRx's HOPE Therapeutics subsidiary has also been advancing its interventional psychiatry strategy.

In September, the company announced that HOPE was training to deploy Zeta Surgical's FDA-cleared robotic TMS system at its Florida clinics.

The technology is designed to support precise and repeatable positioning during TMS treatments, complementing NRx's broader research involving robotic-assisted brain stimulation.

The relationship between HOPE Therapeutics, the SPARC-TMS program, and NRX-101 creates opportunities to connect clinical treatment capabilities with the company's pharmaceutical development programs.

NRX-101 and GNK-301 Add Further Pipeline Potential

Beyond its approved preservative-free ketamine product, NRx continues to pursue additional pharmaceutical development opportunities.

NRX-101 is an investigational oral combination of D-cycloserine and lurasidone being developed for serious depression-related conditions, including suicidal bipolar depression. The company has reported FDA Breakthrough Therapy Designation for this program.

NRX-100, the company's preservative-free intravenous ketamine, also has a separate New Drug Application development pathway for potential depression and suicidal ideation treatment claims. The October 30 ANDA approval applies to the preservative-free ketamine product and does not constitute approval of that separate NDA.

Another development came September 14, when GeNeuro, an NRx company, announced the award of European patent rights for GNK-301, a drug candidate being developed for amyotrophic lateral sclerosis (ALS).

The patent development adds another neurological research opportunity to the company's broader portfolio, although further development and clinical evidence will be required to establish its potential.

NRx Pharmaceuticals: A New Commercial Chapter Begins

NRx Pharmaceuticals has accomplished several important milestones in a relatively short period. The October 19 manufacturing announcement confirmed completion of three commercial process validation lots and two-year room-temperature stability results. The October 30 FDA approval then cleared a major regulatory hurdle. Now, the November 11 announcement confirms that commercial sales operations have commenced, with an experienced national sales force in place and January 2027 shipments targeted.

The company's developing story now includes several interconnected opportunities:

• FDA approval: Preservative-free intravenous ketamine received ANDA approval on October 30.
• Commercial launch: A 17-person national sales force commenced selling operations November 11.
• Market reach: Sales representatives have relationships with purchasers responsible for approximately 80% of current U.S. ketamine sales.
• Revenue opportunity: Initial supply agreements and preorders are targeted for late 2026, with shipments scheduled for January 2027.
• Manufacturing expansion: Contracts with German BFS technology suppliers are intended to double the South Carolina manufacturing footprint.
• Potential margins: Management expects gross and net margins exceeding 50%.
• DARPA research: Approximately $11.25 million in contract funding supports the SPARC-TMS research initiative.
• Additional pipeline: NRX-101, HOPE Therapeutics, and GNK-301 provide further development opportunities.

The Bottom Line: $NRXP Moves From FDA Approval to Commercial Execution

The November 11 announcement may be one of the most important developments in the NRx Pharmaceuticals investment story because it demonstrates that the company is now actively pursuing commercialization of its newly approved product.

FDA approval was a major accomplishment, but the next stage is about sales, customer agreements, product shipments, manufacturing expansion, and ultimately revenue generation.

NRx now has an approved preservative-free ketamine product, an operating national sales force, established relationships reaching a substantial portion of the current U.S. ketamine purchasing market, and plans to begin shipments in January 2027.

The company's ambition extends further. Its investment in BFS manufacturing technology, proposed expansion in South Carolina, and plans to pursue additional sterile injectable products could provide a broader commercial platform over time.

Meanwhile, the DARPA-funded SPARC-TMS program, NRX-101 development, HOPE Therapeutics, and GNK-301 patent development add additional opportunities beyond the immediate ketamine business.

For investors following N A S D A Q: NRXP, the story has evolved considerably: regulatory progress has become FDA approval, manufacturing preparation has become commercial readiness, and commercial readiness has now become active selling operations.

The next major milestones will be the announcement of initial supply agreements, customer preorders, January shipments, actual sales results, and progress on manufacturing expansion. These developments will help determine how successfully NRx translates its recent accomplishments into sustainable commercial growth.

NRx Pharmaceuticals has entered an exciting new chapter, with an approved product and a commercial organization now working to establish its presence in the U.S. sterile injectable market. The opportunity is significant, and the coming months will be particularly important as the company works to turn its regulatory and manufacturing achievements into measurable business results.

For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

Media Contact
Company Name: NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Contact Person: Brian Korb, Managing Partner, astr partners
Email: brian.korb@astrpartners.com
Phone: (917) 653-5122
Country: United States

Disclosure listed on the CorporateAds website

Disclaimer: https://corporateads.com/disclaimer/